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ABSTRACT Recently, two new inﬂuenza A-like viruses have been discovered in bats,
A/little yellow-shouldered bat/Guatemala/060/2010 (HL17NL10) and A/ﬂat-faced bat/Pe-
ru/033/2010 (HL18NL11). The hemagglutinin (HA)-like (HL) and neuraminidase (NA)-like
(NL) proteins of these viruses lack hemagglutination and neuraminidase activities, de-
spite their sequence and structural homologies with the HA and NA proteins of conven-
tional inﬂuenza A viruses. We have now investigated whether the NS1 proteins of the
HL17NL10 and HL18NL11 viruses can functionally replace the NS1 protein of a conven-
tional inﬂuenza A virus. For this purpose, we generated recombinant inﬂuenza A/Puerto
Rico/8/1934 (PR8) H1N1 viruses containing the NS1 protein of the PR8 wild-type,
HL17NL10, and HL18NL11 viruses. These viruses (r/NS1PR8, r/NS1HL17, and r/NS1HL18,
respectively) were tested for replication in bat and nonbat mammalian cells and in mice.
Our results demonstrate that the r/NS1HL17 and r/NS1HL18 viruses are attenuated in
vitro and in vivo. However, the bat NS1 recombinant viruses showed a phenotype similar
to that of the r/NS1PR8 virus in STAT1/ human A549 cells and mice, both in vitro and
in vivo systems being unable to respond to interferon (IFN). Interestingly, multiple
mouse passages of the r/NS1HL17 and r/NS1HL18 viruses resulted in selection of mutant
viruses containing single amino acid mutations in the viral PB2 protein. In contrast to
the parental viruses, virulence and IFN antagonism were restored in the selected PB2
mutants. Our results indicate that the NS1 protein of bat inﬂuenza A-like viruses is less
efﬁcient than the NS1 protein of its conventional inﬂuenza A virus NS1 counterpart in
antagonizing the IFN response and that this deﬁciency can be overcome by the inﬂu-
enza virus PB2 protein.
IMPORTANCE Signiﬁcant gaps in our understanding of the basic features of the re-
cently discovered bat inﬂuenza A-like viruses HL17NL10 and HL18NL11 remain. The
basic biology of these unique viruses displays both similarities to and differences
from the basic biology of conventional inﬂuenza A viruses. Here, we show that re-
combinant inﬂuenza A viruses containing the NS1 protein from HL17NL10 and
HL18NL11 are attenuated. This attenuation was mediated by their inability to antag-
onize the type I IFN response. However, this deﬁciency could be compensated for by
single amino acid replacements in the PB2 gene. Our results unravel a functional di-
vergence between the NS1 proteins of bat inﬂuenza A-like and conventional inﬂu-
enza A viruses and demonstrate an interplay between the viral PB2 and NS1 pro-
teins to antagonize IFN.
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Inﬂuenza A viruses (IAVs) maintain a large reservoir of genetic diversity in animals,including swine, horses, and, in particular, birds, which represent the largest reservoir
of IAVs (1). Recently, two new IAVs have been discovered in bats by metagenomic
approaches, A/little yellow-shouldered bat/Guatemala/060/2010 (HL17NL10) and
A/ﬂat-faced bat/Peru/033/2010 (HL18NL11) (2, 3), changing our understanding of the
inﬂuenza virus ecology. Serological studies have demonstrated a high prevalence of bat
inﬂuenza A-like viruses in Peruvian bats (3). Moreover, cross-reactive antibodies against
avian H9 IAVs have been detected in 30% of sampled African bats, indicating that
infection of bats with IAV is not limited to the HL17 and HL18 viruses (4). Nevertheless,
the HL17NL10 and HL18NL11 viruses have proved to be very particular, since prelim-
inary attempts at isolation were unsuccessful (5, 6), suggesting that they have replica-
tion requirements distinct from those of other conventional IAVs. Moreover, several of
the known canonical functions of the hemagglutinin (HA) and neuraminidase (NA)
proteins of IAVs are missing in the corresponding hemagglutinin-like (HL) and
neuraminidase-like (NL) proteins of inﬂuenza A-like strains (7–12). Recently, infectious
bat inﬂuenza A-like viruses have been generated by reverse genetics (12). These viruses
demonstrate a unique cell type tropism not restricted to bat cells, highlighting the
importance of further research to understand the biology of such viruses and their
potential ability to infect nonbat mammalian hosts.
IAV nonstructural protein 1 (NS1) is a multifunctional virulence factor that performs
a plethora of protein-protein and protein-RNA interactions during IAV infection. None-
theless, the major ascribed NS1 function is as an antagonist of type I interferon (IFN)
(13). At the pretranscriptional level, NS1 is able to bind to double-stranded RNA (dsRNA)
species (14) and to the host proteins RIG-I, TRIM25, and PKR, blocking virus sensing, IFN
induction, and host antiviral activities (15–17). At the co- and posttranscriptional levels,
NS1 interferes with cellular pre-mRNA processing, shutting down host gene expression,
including that of IFN-related genes (13). More interestingly, these interactions have
been proposed to be a species-speciﬁc signature for several inﬂuenza A virus strains
(18–21). In particular, experiments in which the NS1 protein from HL17NL10 and
HL18NL11 (denoted NS1HL17 and NS1HL18 proteins, respectively) was overexpressed
demonstrated the effective speciﬁc inhibition of IFN induction by NS1 but did not
indicate that NS1 blocked general host gene expression (22, 23). However, other
authors showed that truncations of NS1HL17 and NS1HL18 did not dramatically affect
viral lung replication in mice in the context of chimeric viruses containing the glyco-
proteins HA and NA from inﬂuenza A/Puerto Rico/8/1934 (PR8) H1N1 viruses and all the
internal proteins from the HL17NL10 and HL18NL11 viruses (6). Some of the main
functional and structural similarities (and differences) between the NS1 protein from
the bat inﬂuenza A-like viruses and NS1 from the PR8 virus have been previously
described (22, 24).
In the study described here, we generated bat NS1 recombinant HL17NL10 and
HL18NL11 viruses in a conventional PR8 IAV backbone and characterized these viruses
(r/NS1HL17 and r/NS1HL18, respectively) in bat and notbat mammalian cells and in
mice. We show that although these recombinant viruses were able to replicate in cell
culture and in mice, there was an evident attenuation imposed by the NS1 protein of
the bat inﬂuenza A-like viruses. In contrast, the bat recombinant viruses r/NS1HL17 and
r/NS1HL18 showed a phenotype more similar to that of the recombinant PR8 virus
containing the NS1 protein of the PR8 wild type (r/NS1PR8) in STAT1/ (IFN signaling-
deﬁcient) systems. After multiple mouse passages, bat NS1 viruses acquired single
point mutations in the PB2 viral polymerase that reverted their phenotype in mice. In
contrast to the parental r/NS1HL17 and r/NS1HL18 viruses, the viruses containing the
compensatory mutations in PB2 (r/NS1HL17 P5 and r/NS1HL18 P7, respectively) were
able to inhibit IFN production by hindering interferon regulatory factor 3 (IRF3)
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phosphorylation. Our results demonstrate an interplay between the NS1 and the PB2
viral proteins to counteract the host antiviral response.
RESULTS
Bat NS1 recombinant PR8 viruses are attenuated in bat and nonbat mamma-
lian cells and in vivo. It has been demonstrated that the NS1 proteins of bat inﬂuenza
A-like viruses (NS1HL17 and NS1HL18 proteins, respectively) are able to prevent IFN
induction and that this is strictly dependent on their RNA binding domains (22). To
assess if the NS1HL17 and NS1HL18 proteins from bat inﬂuenza A-like viruses could
functionally and efﬁciently replace the NS1 protein of a conventional inﬂuenza A virus,
we used reverse genetics to generate (25) in a PR8 backbone recombinant viruses
containing the NS1 open reading frame (ORF) of the PR8 wild type (WT) (for comparison
purposes), the NS1 ORF of HL17NL10, and the NS1 ORF of HL18NL11 (generating the
r/NS1PR8, r/NS1HL17, and r/NS1HL18 viruses, respectively) (Fig. 1A and B). To prevent
modiﬁcations in the overlapping nuclear export protein (NEP) ORF of the IAV NS gene,
the NS1-coding regions were inserted in a modiﬁed NS segment that expresses the NS1
and NEP proteins as a contiguous ORF separated by a 2A picornaviral sequence that
allows expression of the NS1 and NEP proteins as individual polypeptides (26). The NS1
proteins were also ligated in frame at their N termini with a V5 tag, a small epitope
derived from the P and V proteins of the paramyxovirus simian virus 5 (SV5) (protein
sequence, GKPIPNPLLGLDST). In order to verify NS1 expression from these viruses, we
performed infections in human lung epithelial (A549) cells at a multiplicity of infection
(MOI) of 2 over time for indirect immunoﬂuorescence and Western blotting (Fig. 1C and
D). The r/NS1HL17 and r/NS1HL18 viruses expressed the NS1 and NEP proteins.
Although the NS1 protein expression levels from the bat recombinant viruses were
slightly lower than the NS1 protein expression level from PR8, as measured by Western
blotting, no striking differences in NEP expression level from that in the counterpart
r/NS1PR8 virus were found, suggesting that increased NS1 nuclear localization might be
responsible for decreased NS1 extraction prior to SDS-PAGE and Western blotting,
giving the impression of lower expression levels. However, unlike the NS1 protein from
PR8 (denoted NS1PR8 protein), which showed a varying nuclear and cytoplasmic
distribution depending on the time postinfection (p.i.), the intracellular localization of
the bat inﬂuenza A-like virus NS1 proteins was mainly nuclear at all times tested,
suggesting possible functional differences between NS1 from bat inﬂuenza A-like
viruses and the NS1PR8 protein.
Next, we analyzed the growth properties of the bat NS1 recombinant viruses by
comparing their multicycle growth curves at an MOI of 0.01 in different mammalian cell
lines of bat and nonbat origin. The r/NS1HL17 and r/NS1HL18 viruses showed an
attenuation in growth in cells of canine (Madin-Darby canine kidney [MDCK]) and
human (A549) origin compared to the r/NS1PR8 control virus, with more than 2-log
differences in viral titers being detected at 24 and 36 h postinfection in both cell lines,
respectively (P  0.001) (Fig. 2A). To test whether this reduction in viral titers was
related to an intrinsic host feature present in cells of bat origin, we assessed the
replication ability of these viruses in primary kidney cell lines from Sturnira lilium and
Artibeus lituratus bats, the two South American species of microbats in which these
viruses were ﬁrst discovered in 2012 and 2013 (2, 3). The primary kidney bat cell lines
supported replication of all the tested viruses (Fig. 2B); however, the recombinant
viruses containing a bat virus NS1 were still signiﬁcantly attenuated compared to the
corresponding r/NS1PR8 control.
In order to assess the impact of the substitution of the NS1PR8 protein for the
NS1HL17 and NS1HL18 proteins on virus replication and pathogenesis in vivo, we
infected C57BL/6 mice intranasally with 105, 104, and 103 PFU of the recombinant
viruses and determined their body weights postinfection as an indication of disease
severity as well as mortality. In addition, lungs from mice infected with 105 PFU were
used for the assessment of virus replication at days 2 and 4 postinfection. Similar to
their behavior in tissue culture, the r/NS1HL17 and r/NS1HL18 viruses were attenuated
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in mice compared to the r/NS1PR8 control virus. While the r/NS1PR8 virus induced 75%
mortality at an infectious dose of 104 PFU, none of the mice died or showed signiﬁcant
signs of morbidity after infection with 104 PFU of the r/NS1HL17 and r/NS1HL18 viruses
(P  0.01) (Fig. 3A). Although these viruses were lethal at 105 PFU, they demonstrated
reduced viral replication (almost 3 logs) compared to that of the r/NS1PR8 virus in lung
homogenates at days 2 (P  0.001) and 4 (P  0.01) postinfection (Fig. 3B).
Bat NS1 recombinant PR8 viruses regain their replication ability and virulence
in IFN signaling-deﬁcient systems. It is well-known that the NS1 protein of inﬂuenza
viruses has evolved mechanisms to evade the antiviral host innate immune responses
FIG 1 Generation of bat NS1 recombinant viruses. (A) Representation of the WT PR8 NS segment and mutated bat inﬂuenza A-like
NS segment. (B) Color-coded illustration of genes included in recombinant NS1 viruses. Blue, genes from PR8; green, chimeric NS
segment indicating the shifted NS1 ORF for PR8, HL17NL10, and HL18NL11. (C) Determination by Western blotting of NS1 expression
levels in A549 cells infected at an MOI of 2 (or mock infected []) at the indicated times p.i. Lysates were prepared at 6, 10, and 16
h p.i. NS1, the V5 tag, and NP were detected using speciﬁc antibodies. -Actin served as a loading control. (D) Indirect immuno-
ﬂuorescence of NS1 protein localization in A549 cells infected at an MOI of 2 at the indicated times p.i. Costaining was performed
using a polyclonal anti-NS1 serum (NS1-155; green) and anti-V5 tag (red), together with 4=,6=-diamidino-2-phenylindole (DAPI) to
stain the nuclei (blue).
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(27). Thus, we investigated whether the attenuation of bat NS1 recombinant viruses
was due to reduced IFN antagonism. For that, we determined viral replication in
engineered clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9
A549 cells unable to respond to type I IFN (A549 STAT1/ cells). To generate the
STAT1-deﬁcient A549 cell line, we followed a previously described protocol (28) tar-
geting exon 7 of the human STAT1 locus by guide RNA (gRNA). After transfection of the
Cas9 expression plasmid and the gRNA, cloned cells were screened for the loss of
expression of STAT1 by Western blotting and the loss of IFN signaling by quantitative
reverse transcription-PCR (qRT-PCR) of mRNAs derived from IFN-stimulated genes (ISGs)
after IFN stimulation (Fig. 2C and D). We performed multicycle growth curves of the NS1
recombinant viruses in STAT1-deﬁcient A549 cells after infection at an MOI of 0.01.
Although there was a slight decrease in virus titers for the bat NS1 recombinant viruses
compared to those for r/NS1PR8 at late times postinfection, these differences were not
statistically signiﬁcant (Fig. 2A). This is in contrast to the results for wild-type A549 cells.
These data suggest that NS1 from bat inﬂuenza A-like viruses antagonizes the type I IFN
pathway to a lesser extent than the NS1 protein from the PR8 virus in the context of IAV
infection in vitro.
We next compared the sensitivity of WT control (strain 129S6/SvEv) and STAT1/
mice to infection by bat NS1 recombinant viruses (Fig. 4A and B). Mice of both
genotypes were intranasally infected with 105, 104, and 103 PFU of the r/NS1HL17,
FIG 2 Characterization of bat NS1 recombinant viruses in vitro. (A and B) Viral growth of r/NS1HL17, r/NS1HL18, and r/NS1PR8 in MDCK
(canine), A549 (human), and A549 STAT1/ (human) cells and in primary kidney bat cell lines from Sturnira lilium and Artibeus lituratus.
Cells were infected at an MOI of 0.01, and the viral supernatant was titrated as the number of PFU per milliliter at the indicated time
points postinfection (p.i.). Shown are the means and SDs from three biological replicates. ANOVA for multiple comparisons was used,
and those that were statistically signiﬁcant (P  0.05) were compared in groups two by two and the Bonferroni correction was applied
(***, P  0.001; **, P  0.01). (C and D) Generation of a STAT1 knockout A549 cell line using the CRISPR-Cas9 method. (C) qRT-PCR
analyses of representative interferon-stimulated gene (ISG) induction in vitro. WT and STAT1 KO cells were treated with 1,000 units of
universal IFN for 12 h. Cells were harvested, and total RNA was isolated and subjected to RT-PCR to measure the transcriptional
induction of the indicated interferon-induced genes. (D) The WT and STAT1 KO cell lines were tested for STAT1 expression by Western
blotting using STAT1- and actin-speciﬁc antibodies. Rel., relative; -/-, STAT1/ cells.
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r/NS1HL18, and r/NS1PR8 viruses, and morbidity and mortality were recorded. Inter-
estingly, the r/NS1HL17 and r/NS1HL18 viruses induced similar morbidity and displayed
50% mouse lethal doses (MLD50) similar to the MLD50 of the r/NS1PR8 virus (Fig. 4B).
Moreover, when we assessed viral replication in WT and STAT1/ mouse lungs after
2 days postinfection with 105- and 104-PFU infectious doses, respectively, we found that
the r/NS1HL17 and r/NS1HL18 virus titers were closer to the r/NS1PR8 virus titers in
FIG 3 Characterization of bat NS1 recombinant viruses in vivo. (A) Six- to 8-week-old C57BL/6 mice were infected intranasally with the indicated amounts of
viruses, and PBS was used for mock infection (gray). Mean body weights and Kaplan-Meier curves are shown (n  5 mice/group). Error bars represent SDs.
ANOVA for multiple comparisons was used to compare the body weights at each time point, and those that were statistically signiﬁcant (P  0.05) were
compared in groups two by two and the Bonferroni correction was applied (***, P  0.001 for r/NS1PR8 versus r/NS1HL17 and r/NS1HL18). The Mantel-Cox test
was used to compare survival (**, P  0.01). (B) Viral lung titers (in numbers of PFU per milliliter per lung; n  4 mice/group) at a 105-PFU total infectious dose
at days 2 and 4 postinfection. Horizontal lines, mean values and SDs. ANOVA for multiple comparisons was used to compare the viral lung titers at each time
point, and those that were statistically signiﬁcant (P  0.05) were compared in groups two by two and the Bonferroni correction was applied (***, P  0.001;
**, P  0.01).
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FIG 4 Characterization of bat NS1 recombinant viruses in mice unable to respond to type I IFN because of disruption of the STAT1 gene.
(A) Six- to 8-week-old 129S6/SvEv WT mice were infected intranasally with the indicated amount of viruses, and PBS was used for mock
(Continued on next page)
The NS1 Protein of Bat Inﬂuenza A-Like Viruses Journal of Virology
April 2018 Volume 92 Issue 7 e02021-17 jvi.asm.org 7
 o
n
 M
arch 20, 2018 by UNIV DE CO
STA RICA SISTEM
A DE
http://jvi.asm.org/
D
ow
nloaded from
 
STAT1/mice than WT mice (Fig. 4C). The results indicate that most of the attenuation
of the r/NS1HL17 and r/NS1HL18 viruses compared to the activity of the r/NS1PR8 virus
was lost in IFN signaling-deﬁcient (STAT1/) mice.
Serial passage of bat NS1 recombinant viruses in mice resulted in phenotypic
reversion due to mutations in the C-terminal domain of PB2. Next, we serially
passaged the bat NS1 recombinant viruses in mice in order to investigate whether their
attenuation could be overcome by the selection of compensatory mutations. Two mice
per virus were infected with 105 PFU, and after 3 days the mice were euthanized and
the lungs were excised. After lung homogenization, subsequent mice were infected
with 50 l of the resulting supernatant. Viral lung titers and body weight loss were
monitored after every passage, with signiﬁcant increases being detected at passages 5
and 7 for viruses expressing the NS1 proteins of HL17NL10 and HL18NL11 (r/NS1HL17
P5 and r/NS1HL18 P7, respectively) (Fig. 5A). RNA isolated from lung homogenate
supernatants was subjected to Sanger sequencing. The resulting viral genome se-
quence analysis revealed two different amino acid substitutions in the PB2 gene of each
virus provided by the PR8 IAV H1N1 backbone: I503V (A1510G; ATC ¡ GTC) in
r/NS1HL17 P5 and V249A (T749C; GTG¡ GCG) in r/NS1HL18 P7. Also, in the r/NS1HL17
P5 virus, a new start codon resulted in the insertion of 7 amino acids (aa) upstream of
the V5 tag in the NS segment. One silent mutation was also identiﬁed in the PA gene
of the r/NS1HL17 P5 virus, P653P (A1959G; CCA¡ CCG), and one was identiﬁed in the
PB2 gene of the r/NS1HL18 P7 virus, G222G (T666A; GGT¡ GGA). Remarkably, no other
nonsynonymous mutations were present in the mouse-passaged viruses at the level of
resolution of Sanger sequencing.
According to the published crystal structure of the HL17NL10 PB2 protein (29), both
the I503V and V249A mutations are located relatively close together, in the linker
regions of the protein without known functional properties and outside the well-
characterized cap-binding domain (Fig. 5B). After alignment of 12,996 unique PB2
sequences obtained from the Inﬂuenza Research Database (http://www.ﬂudb.org) rep-
resenting IAV strains from different years and hosts, including strains of swine, avian,
human, and bat origin (Fig. 5B), we noticed that the I503V substitution in r/NS1HL17
was a change to the most common amino acid residue at that position in the PB2
protein of inﬂuenza viruses (including also the HL17NL10 and HL18NL11 viruses).
However, the original valine in the r/NS1HL18 parental virus at position 249 was
conserved in the vast majority of strains aligned (99.9%), while its replacement by the
alanine present in r/NS1HL18 P7 was found in only a very few strains, including in the
PB2 of both bat inﬂuenza A-like viruses, HL17NL10 and HL18NL11.
Compensatory mutations found in mouse-passaged viruses restore virulence
and IFN antagonism. It has previously been described that IAV polymerase complex
proteins contribute to counteracting antiviral host responses (30–37). Thus, we inves-
tigated whether the selected PB2 protein single mutations compensated for the loss of
ﬁtness of the original bat NS1 recombinant viruses through an enhancement of IFN
antagonism. For that, we plaque puriﬁed the r/NS1HL17 P5 and r/NS1HL18 P7 viruses
in MDCK cells and ampliﬁed them in eggs once in order to generate a working stock
for later characterization. First, we determined the phenotype of the mouse-passaged
viruses compared to that of the parental ones in vitro. For that, multicycle growth
curves were performed at an MOI of 0.01 in MDCK and A549 cells. As shown in Fig. 6A,
FIG 4 Legend (Continued)
infection. Mean body weights and Kaplan-Meier curves are shown (n  5 mice/group). Error bars represent SDs. The Mantel-Cox test was
used to compare survival (**, P  0.01). (B) Six- to 8-week-old 129S6/SvEv STAT1/ mice were infected intranasally with the indicated
amounts of viruses, and PBS was used for mock infection (gray). Mean body weights and Kaplan-Meier curves are shown (n  5
mice/group). Error bars represent SDs. ANOVA for multiple comparisons was used to compare the body weights at each time point, and
those that were statistically signiﬁcant (P  0.05) were compared in groups two by two and the Bonferroni correction was applied (*, P 
0.05 for r/NS1PR8 versus r/NS1HL17 and r/NS1HL18). (C) Viral lung titers (in numbers of PFU per milliliter per lung; n  4 mice/group) at
104- and 105-PFU total infectious doses for 129S6/SvEv STAT1/ and 129S6/SvEv WT mice, respectively. Horizontal lines, mean values and
SDs at day 2 p.i. ANOVA for multiple comparisons was used to compare viral lung titers, and those that were statistically signiﬁcant (P 
0.05) were compared in groups two by two and the Bonferroni correction was applied (*, P  0.05).
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FIG 5 Multiple mouse passages of bat NS1 recombinant viruses resulted in compensatory mutations in PB2. (A) Six-
to 8-week-old C57BL/6 mice were infected intranasally with the indicated amount of viruses. Lungs were excised
on day 3 postinfection. The resulting supernatants were used to determine lung viral titers and for further
inoculations in mice. Illustrations also show body weight (BW) loss (in percent; bars, left axis) and viral lung
titers (in numbers of PFU per milliliter; dots, right axis) of mice in every passage for the r/NS1HL17 and
r/NS1HL18 viruses. (B) Superimposition of the crystal structure of the HL17NL10 polymerase complex (29). The
space-ﬁlling representation is color coded according to the different subunits (gray, PA; white, PB1; blue, PB2),
with the cap-binding subdomain being highlighted in orange. The selected mutations after mouse passages
are shown in red (V249A and I503V). Highlighted squares represent the region of PR8 and HL17NL10 from aa
244 to 254 and aa 498 to 508 after multiple-sequence alignment of viruses from multiple hosts and years and
of different subtypes. PB2 sequences (n  12,996 unique PB2 sequences) were obtained from the Inﬂuenza
(Continued on next page)
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after acquiring the compensatory mutations, the recombinant viruses showed an
advantage in replication compared to the parental viruses, which was particularly
signiﬁcant for the r/NS1HL17 P5 virus. Interestingly, the V249A and I503V PB2 mutations
did not result in increased polymerase activity, as measured by a minigenome luciferase
reporter assay, suggesting that the minigenome polymerase activity assay may not
recapitulate completely the replication properties of the r/NS1HL17 P5 and r/NS1HL18
P7 viruses within the context of infection. Nonetheless, the attenuated replication of
the r/NS1HL18 P7 virus in MDCK and A549 cells was consistent with a reduced
polymerase activity associated with the V249A PB2 amino acid substitution, as mea-
FIG 5 Legend (Continued)
Research Database (https://www.ﬂudb.org/brc/home.spg?decoratorinﬂuenza). Consensus sequences in the
vicinity of the selected mutations and the percentages of amino acids of interest are shown for the
representative viruses. Black, A/Puerto Rico/8/1934 (GenBank accession number AF389115.1); red, A/little
yellow shouldered bat/Guatemala/153/2009 (GenBank accession number CY103873.1).
FIG 6 Enhancement of replication properties but not polymerase activity of the recombinant viruses
after selection of the compensatory mutations. (A) Viral growth properties of r/PR8, r/NS1PR8, r/NS1HL17,
r/NS1HL17 P5, r/NS1HL18, and r/NS1HL18 P7 in MDCK (canine) and A549 (human) cells. Cells were
infected at an MOI of 0.01, and the viral supernatant was titrated as the number of PFU per milliliter at
the indicated time points postinfection (p.i.). Shown are the means and SDs from three biological
replicates. ANOVA for multiple comparisons was used, and those that were statistically signiﬁcant (P 
0.05) were compared in groups two by two and the Bonferroni correction was applied (***, P  0.001).
(B) Minigenome polymerase activity assay of PB2 from the PR8 strain and mutated PB2 V249A and I503V
in HEK293T cells (human). The ﬁreﬂy total luciferase level was measured at 24 h posttransfection. The
values were averaged and normalized to the values for Renilla luciferase. Mean luminescence levels
relative to those for mock-transfected cells are shown.
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sured by reconstitution of the RNA-dependent RNA polymerase together with the
nucleoprotein (NP) in a minigenome luciferase reporter assay (Fig. 6B).
Next, we measured the expression of beta IFN (IFN-) mRNA in human A549 cells by
quantitative PCR (qPCR) after infection (MOI, 10). After 6 h p.i., total RNA was extracted
and reverse transcription was performed using oligo(dT). Subsequently, quantiﬁcation
of mRNA was performed using speciﬁc primers against IFN-. The values were normal-
ized against those for mock-infected samples. As shown in Fig. 7A, the r/NS1HL17 and
r/NS1HL18 viruses induced more IFN-mRNA than the control recombinant PR8 (r/PR8)
virus, demonstrating a defect of the NS1 from bat inﬂuenza A-like viruses in inhibiting
IFN induction in the context of IAV infections. Interestingly, the V249A and I503V PB2
mutations did not result in increased inhibition of IFN induction when overexpressed
(Fig. 7B). However, the viruses containing the PB2 compensatory mutations regained
the IFN antagonism ability, as indicated by their lower levels of IFN- mRNA induction
in virus-infected human A549 cells. Remarkably, both viruses containing the compen-
satory mutations, r/NS1HL17 P5 and r/NS1HL18 P7, blocked the activation of IRF3 in
human A549 cells (MOI, 5) after 6 h p.i., as determined by measurement of reduced
levels of IRF3 phosphorylation and translocation into the nucleus in virus-infected cells
(Fig. 7C and D) compared with the levels in cells infected with the parental r/NS1HL17
and r/NS1HL18 viruses. No differences in NS1 intracellular localization were found
between the parental and the mouse-passaged viruses by immunoﬂuorescence. Al-
though higher levels of V5-NS1 were detected by Western blotting (Fig. 7D) for the
mouse-adapted viruses than for the parental ones, no differences in the expression
levels of NEP were found (data not shown).
Next, we determined the phenotype of the r/NS1HL17 P5 and r/NS1HL18 P7 viruses
compared to that of their parental ones in vivo. For that, C57BL/6 mice were subjected
to infection with the r/NS1HL17 and r/NS1HL18 viruses and the viruses containing the
compensatory mutations at 104, 103, and 10 total PFU, with the WT r/PR8 virus (and
r/NS1PR8; data not shown) being used as a positive control. As shown in Fig. 8A, in the
body weight loss and Kaplan-Meier curves, the adapted viruses showed an advantage
over the parental ones, as the bat NS1-containing viruses regained virulence in mice to
levels similar to but not higher than those in r/PR8. This phenotype was also conﬁrmed
according to the mouse viral lung titers, with higher levels of replication being found
for the r/NS1HL17 P5 and r/NS1HL18 P7 viruses at day 2 p.i. (Fig. 8B). Moreover, when
we measured the level of IFN- mRNA in the mouse lungs after infection at the same
infectious dose (Fig. 8C), both viruses with the selected compensatory mutations,
r/NS1HL17 P5 and r/NS1HL18 P7, revealed a clear enhancement of IFN antagonism. To
conﬁrm that the phenotypic reversion was due to the acquired PB2 mutations, we also
rescued recombinant viruses not containing mutations in any other genes but con-
taining the PB2 single point mutations, r/NS1HL17 I503V and r/NS1HL18 V249A, by
reverse genetics. Then we infected mice with these viruses at 105 PFU and excised the
lungs at day 2 to assess viral replication. The experiments revealed that the recombi-
nant viruses containing single PB2 mutations still showed enhanced replication prop-
erties compared to those of r/NS1HL17 and r/NS1HL18 (Fig. 8D), demonstrating that the
acquisition of the compensatory mutations in the PB2 protein (I503V and V249A) is
responsible for the regained phenotype observed in the previous experiments with the
r/NS1HL17 P5 and r/NS1HL18 P7 viruses in vitro and in vivo.
DISCUSSION
In this study, we generated recombinant inﬂuenza viruses expressing the NS1
proteins of the bat inﬂuenza A-like HL17NL10 and HL18NL11 viruses in a PR8 backbone
and tested the speciﬁc impact of these NS1 proteins in the context of an infection both
in mammalian cells and in mice. Our results demonstrate that the bat r/NS1HL17 and
r/NS1HL18 viruses have impaired IFN antagonism compared to the r/NS1PR8 control
virus. Speciﬁcally, the r/NS1HL17 and r/NS1HL18 viruses were attenuated for replication
in MDCK and A549 cells and mouse lungs and displayed less virulence in mice than the
control r/NS1PR8 virus. However, their attenuation properties were signiﬁcantly re-
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FIG 7 Compensatory mutations found in mouse-passaged viruses restore IFN antagonism. (A) qRT-PCR analyses of IFN- induction in
vitro. A549 cells were infected with the indicated amount of virus. Cells were harvested after 6 h postinfection (p.i.). Total RNA was
extracted, and the levels of IFN- mRNA were quantiﬁed in triplicate by qPCR. The values were averaged and normalized to those for
18S mRNA. Mean induction levels relative to the mRNA levels in mock-infected cells are shown. (B) IFN- promoter assay in human
HEK293T cells of PB2 from the PR8 strain and mutated PB2 V249A and I503V. Cells were cotransfected with expression plasmids
expressing the indicated proteins for 24 h. NS1 from PR8 was used as a control. After infection with a DI-rich SeV preparation for a
further 16 h, the amount of ﬁreﬂy total luciferase was determined. Values were normalized to the value for the empty vector plus SeV
(for which the value was set to 100%). (C) Indirect immunoﬂuorescence of IRF3 localization in A549 cells infected at an MOI of 5 at
6 h p.i. Costaining was performed using rabbit anti-IRF3 (green), goat anti-V5 tag (light blue), and mouse anti-NP (red) together with
4=,6=-diamidino-2-phenylindole (DAPI) to stain the nuclei (blue). (D) Determination by Western blotting of protein expression levels in
A549 cells infected at an MOI of 5 (or mock infected []). Lysates were prepared for the indicated times p.i. Phospho-IRF3 (pIRF3), IRF3,
the V5 tag, NP, and PB2 were detected using speciﬁc antibodies. -Actin served as a loading control.
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FIG 8 Antagonism of type I IFN confers virulence to bat inﬂuenza A-like viruses containing the compensatory mutations. (A) Six- to
8-week-old C57BL/6 mice were infected intranasally with the indicated amount of viruses; PBS was used for mock infection (gray), and
r/PR8 was used as a control. Mean body weights and Kaplan-Meier curves are shown (n  4 mice/group) for mice infected with the
NS1 parental recombinant viruses compared to those for mice infected with the mouse-adapted viruses. Horizontal lines, mean values
and SDs. The Mantel-Cox test was used to compare survival (***, P  0.001). (B) Viral lung titers (in numbers of PFU per milliliter per
lung; n  4 mice/group) at a 105-PFU total infectious dose at days 2 and 4 postinfection. Horizontal lines, mean values and SDs. (C)
qRT-PCR analyses of IFN- induction in vivo. Six- to 8-week-old C57BL/6 mice (2 mice per group) were infected intranasally with a
(Continued on next page)
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verted in IFN signaling-deﬁcient (STAT1/) cells and mice. Thus, this indicates that an
impaired IFN antagonism conferred by the substitution of the WT IAV NS1 protein for
the NS1 proteins of bat inﬂuenza A-like viruses is likely responsible for their attenuation.
Indeed, infection with bat NS1-expressing IAVs resulted in higher levels of IRF3 activa-
tion and IFN induction in cells and mice, consistent with an impaired ability of the NS1
from bat inﬂuenza A-like viruses to block the RIG-I-sensing pathway and IFN induction
in virus-infected cells. Thus, despite the observed inhibition of IFN induction in the
context of overexpression (22, 23), the NS1 proteins of bat inﬂuenza A-like viruses are
less capable of inhibiting IFN induction than the NS1 protein from a conventional IAV
in the context of infection, illustrating that overexpression of a gene product may lead
to biologically misleading conclusions compared to those drawn after productive viral
replication in mammalian systems.
Bat NS1-mediated attenuation of viral replication was not restricted to nonbat cells.
IAVs expressing the NS1 from bat inﬂuenza A-like viruses were also attenuated in cells
derived from the bat species in which these viruses were discovered. Nonetheless, it is
still possible that some speciﬁc features of the bat immune system are not totally
present in the in vitro model studied here; thus, further studies in bats are necessary in
order to dissect the speciﬁc virus-host interactions of these unconventional inﬂuenza
viruses.
After serial passaging in mice, compensatory mutations in the viral polymerase
subunit PB2 were acquired by both r/NS1HL17 and r/NS1HL18, demonstrating the
versatility of inﬂuenza viruses in overcoming host restriction barriers. These mutations
translated into a more effective inhibition of IFN-mediated antiviral responses and in
the restoration of viral replication and lethality in mice. Although one of the passaged
viruses also contained a small amino acid insertion in the NS1 gene (7 aa), this appeared
to be an irrelevant passenger mutation. As shown in Fig. 8D, phenotypic reversion
mapped to the PB2 mutation and not to the NS1 mutation, as determined by the rescue
of recombinant viruses containing single mutations by reverse genetics. However, the
lung viral titers of r/NS1HL17 I503V and r/NS1HL18 V249A showed a slight decrease
compared to those of the mouse-passaged viruses. Thus, the possibility that the
synonymous replacements also identiﬁed in the mouse-adapted bat NS1-containing
viruses made a speciﬁc contribution cannot be ruled out.
Our results therefore indicate an interplay between the viral polymerase and the
NS1 protein in viral evasion of the host innate immune system. It is plausible that in bat
inﬂuenza A-like viruses the PB2 proteins also compensate for the weak IFN antagonism
by their NS1 proteins. Consistent with this, the PB2 proteins of both the HL17 and HL18
viruses have a V249A substitution. Further experimentation is required to identify the
mechanisms by which the PB2 mutations increase IFN antagonism of the bat NS1-
containing viruses. Interestingly, the PB2 V249A and I503V mutations did not result in
increased polymerase activity (Fig. 6B) or in increased inhibition of IFN induction when
overexpressed (Fig. 7B). Further research will be needed to identify the mechanism
responsible for the epistatic interactions between the NS1 and PB2 proteins in pre-
venting the induction of IFN.
It is still intriguing how bats can harbor a large diversity of emerging viruses, such
as rabies virus or other paramyxoviruses, often asymptomatically, since no major
differences between the immunology of bats and the immunology of other mammals
have been found. Remarkably, some of the main players of the innate immune
response against viruses, such as pattern Toll-like receptors and RIG-I-like helicases,
have previously been identiﬁed in some species of bats. Moreover, IFN and ISGs are
FIG 8 Legend (Continued)
105-PFU total infectious dose. Lungs were harvested after 6 h postinfection (p.i.). Total RNA was extracted, and the levels of IFN-
mRNA were quantiﬁed in triplicate by qPCR. Values were averaged and normalized to those for 18S mRNA. Mean induction levels
relative to the mRNA levels in mock-infected mice are shown. (D) Six- to 8-week-old C57BL/6 mice were infected intranasally with the
indicated amount of viruses using r/PR8 as a control. Viral lung titers (in numbers of PFU per milliliter per lung; n  4 mice/group)
at a 105-PFU total infectious dose at day 2 postinfection are shown. Horizontal lines, mean values and SDs.
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upregulated upon cellular recognition of viral infection in bat cells (38–44). Although no
human infections with the bat inﬂuenza A-like viruses have been reported so far, there
is still the possibility that HL17NL10 and HL18NL11 may overcome host restriction
barriers, as has happened with other inﬂuenza viruses in the past (e.g., the pandemic
[H1N1] 2009 virus) (45). Unraveling the complex mechanisms of the virus-host inter-
action of HL17NL10 and HL18NL11 will help to clarify the zoonotic potential of these
divergent inﬂuenza viruses.
MATERIALS AND METHODS
Plasmid constructions. Modiﬁed NS segments containing the NS1-coding sequence from inﬂuenza
A/Puerto Rico/8/1934 (PR8), A/little yellow-shouldered bat/Guatemala/060/2010 (HL17NL10), or A/ﬂat-
faced bat/Peru/033/2010 (HL18NL11) (2, 3) and the NEP-coding sequence from PR8 were cloned into the
ambisense pDZ rescue vector (46). The NS segments were modiﬁed to prevent the splicing mechanism
and translate the NS1 and NEP proteins independently, as previously described (26). In addition, the
packaging signal, consisting of the ﬁrst 109 nucleotides from the PR8 NS segment with a mutated start
codon, was duplicated at the beginning of the segment, to ensure efﬁcient packaging into the viral
particle. The V5 tag sequence was fused to the N terminus of the NS1 ORFs to facilitate immune
detection. The modiﬁed V5-NS1 ORFs from PR8, HL17NL10, and HL18NL11 were followed by the porcine
teschovirus 1 (PTV-1) 2A autoproteolytic cleavage site (ATNFSLLKQAGDVEENPGP) and the entire se-
quence of the NEP ORF from PR8.
Virus rescue. Virus rescues were performed as previously described by the eight-plasmid reverse
genetics system in PR8 (5, 25). These viruses, r/NS1PR8 (for comparison purposes), r/NS1HL17, and
r/NS1HL18 or r/NS1HL17 I503V and r/NS1HL18 V249A, were plaque puriﬁed in MDCK cells and passaged
in eggs once in order to generate a working stock. Rescued recombinant NS1 viruses were conﬁrmed by
sequencing, and viral titers were determined by plaque assay in MDCK cells.
Cell lines. Human embryonic kidney 293T (HEK293T) cells, Madin-Darby canine kidney (MDCK) cells,
and human lung epithelial (A549) cells were originally purchased from the American Type Culture
Collection (ATCC). A master cell bank was created for each cell line after purchase, and early-passage cells
were thawed in every experimental step. Once in culture, cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U penicillin per ml, and
100 mg streptomycin per ml for not longer than 2 months to guarantee genotypic stability. The cells
were also monitored by microscopy. For preparation of bat cell lines, bats were sampled between 2014
and 2015 in Costa Rica and captured using mist nets that were set at a height of 2 m in open areas near
drinking or feeding sites to maximize capture success. Tissue samples from different organs were
obtained to establish primary cell cultures. Brieﬂy, tissue fragments were incubated for 30 to 60 min at
37°C in a solution of 0.2 Wunsch units/ml of Liberase (Sigma-Aldrich) in DMEM–nutrient mixture F-12
(DMEM–F-12) (Thermo Fisher) and 1% penicillin-streptomycin (Thermo Fisher). Digestion was stopped by
adding warm DMEM–F-12 completed with 15% FBS (HyClone) and 1% penicillin-streptomycin. Tissue was
mechanically dislodged by pipetting, followed by several centrifugations and washing steps. The pellet
was resuspended and plated in a cell culture-ready ﬂask and incubated at 37°C in 5% CO2 for 5 to 7 days
to allow cell migration from within the tissue fragments and attachment to the ﬂask surface. Primary
kidney cells from Sturnira lilium and Artibeus lituratus bats were immortalized by expressing human
telomerase reverse transcriptase (hTERT) through lentiviral transduction and maintained in DMEM–F-12
supplemented with 20% bovine calf serum (BCS), 100 U penicillin per ml, and 100 mg streptomycin per
ml. For generation of the STAT1/ A549 cell line, we followed the CRISPR-Cas9 protocol described
before (28). Speciﬁcally, exon 7 of the human STAT1 locus (sequence, CCTGTATTGGGGGGCCGCCCAAT)
was targeted by designing gRNA against it and using the open-source CRISPR design tool (http://crispr
.mit.edu/). The gRNA was cloned into the pSpCas9(BB)-2A-GFP (PX458) plasmid vector and transfected
into A549 cells. At 48 h posttransfection, green ﬂuorescent protein (GFP)-positive cells were sorted by
ﬂuorescence-activated cell sorting and plated for colony formation. Single-cell-derived colonies were
picked and screened for STAT1 knockout (KO) by Western blotting. Cell clones negative for STAT1 protein
expression were expanded and used for the experiments (Fig. 2C and D).
Infection of cell cultures. MDCK, A549, STAT1/ A549, and primary kidney bat cell monolayers in
6-well plates were infected with the virus suspension at an MOI of 0.01 in DMEM containing 0.2% bovine
serum albumin (BSA). After 1 h, the infection medium was removed and the cells were incubated with
2 ml of DMEM–0.2% BSA and supplemented with 0.5 to 1 g of TPCK (tosylsulfonyl phenylalanyl
chloromethyl ketone)-treated trypsin/ml, according to the speciﬁc requirement of each cell line, to allow
the production of fusion-competent viruses. Supernatants were collected at 12, 24, 36, and 48 postin-
fection, and viral titers were determined by plaque assay in MDCK cells.
Infection of mice. Mouse experiments were performed using 6- to 8-week-old female mice.
Speciﬁc-pathogen-free C57BL/6 and 129S6/SvEv mice were purchased from The Jackson Laboratory and
Taconic Biosciences, respectively, while homozygous STAT1 KO mice on a 129/Sv mouse background
(129S6/SvEv-Stat1tm1Rds) were initially purchased from Taconic Biosciences (27). The latter STAT1/mice
were then bred locally. Animals had free access to food and water and were kept on a 12-h light and 12-h
dark cycle. All animal experiments were designed to address the principles of the 3 Rs (reduction
[minimal number of mice required for assessment of statistically signiﬁcant differences in pulmonary
virus titers and body weights], reﬁnement [all procedures performed were designed to cause minimal
pain or distress, resulting in better animal well-being during the duration of the experiment], and
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replacement [the mouse is the smallest mammalian animal model that supports inﬂuenza virus repli-
cation]), and all efforts were made to minimize suffering. For virus inoculation, each mouse was
anesthetized by inhalation of 4% isoﬂurane. The mice were monitored daily and euthanized if they lost
more than 25% of their body weight after virus inoculations. Euthanasia of the mice was conducted by
inhalation of 2% CO2 followed by cervical dislocation. The lungs were excised on day 2 or 4 postinfection.
Following homogenization and centrifugation (10,000  g, 20 min, 4°C), the resulting supernatants
were used to determine the viral titer to assess replication. Bat recombinant NS1-containing viruses were
serially passaged in mice to allow the selection of compensatory mutations. For this, mice were
inoculated at 105 PFU (50 l) at passage 0 (P0). The animals were euthanized at 3 days postinfection, and
the lungs were excised. Lung supernatants were used for further inoculations in mice. The experimental
endpoint was established as a signiﬁcant increase in the viral lung titers and a body weight loss of greater
than 10 to 15% compared to the titers and body weights of mice inoculated with the original NS1 bat
recombinant viruses. These experiments were not expected to generate viruses more virulent than the
virus with the parental WT PR8 backbone.
Immunoﬂuorescence. A549 cells were seeded in glass-bottom plates and infected following stan-
dard procedures. After incubation, the cells were ﬁxed with 4% paraformaldehyde and permeabilized
with a solution of phosphate-buffered saline (PBS) containing 0.2% Triton X-100 for 10 min (Sigma). Then,
the cells were washed and stained for 1 h with primary antibodies, followed by staining with ﬂuorescence
secondary antibodies in a 5% bovine serum albumin (BSA; Thermo Scientiﬁc) solution in PBS. Primary
antibodies against the nucleoprotein (NP; 71372; Santa Cruz), V5 tag (9137; Abcam), and interferon
regulatory factor 3 (IRF3; 11904; Cell Signaling) were purchased from the indicated suppliers. The
antibody against the NS1 protein (NS1-155) was kindly provided by Peter Palese (47).
Western blotting. Lysates were prepared under the conditions indicated above in each experiment
and subjected to SDS-PAGE, followed by transfer to polyvinylidene diﬂuoride membranes. Next, the
membranes were incubated overnight with primary antibodies followed by 1 h of incubation with
secondary antibodies in a 5% bovine serum albumin (BSA; Thermo Scientiﬁc) solution in Tris-buffered
saline and 0.1% Tween 20. Primary antibodies against the nucleoprotein (NP; A01506-40; GenScript), V5
tag (46-0805; Invitrogen), polymerase 2 (PB2; GTX125926; Genetex), NS1 protein (NS1-155) (47), nuclear
export protein (NEP; A01499-100; GenScript), M1 protein (127356; Genetex), M2 protein (125951;
Genetex), interferon regulatory factor 3 (IRF3; 11904; Cell Signaling), phospho-interferon regulatory factor
3 (pIRF3; 4947; Cell Signaling), and signal transducer and activator of transcription (STAT1; 3987; Abcam)
were purchased from the indicated suppliers. -Actin served as a loading control.
qRT-PCR. Total RNA from the infection experiments or total RNA stimulated with the type I IFN
protein (R&D Systems) was isolated using an EZNA HP total RNA isolation kit (Omega) or a Direct-zol RNA
miniprep kit (Zymo Research) for in vitro and in vivo approaches, respectively. Reverse transcription was
performed using a high-capacity cDNA reverse transcription kit (Applied Biosystems) and speciﬁc
primers, oligo(dT), or random primers in every case. Real-time qPCR was performed in 384-well plates for
three individual biological samples, and the RNA in each of the samples was measured in triplicate using
SYBR green I master mix (Roche) in a Roche LightCycler 480 system. Relative mRNA values were
calculated using the ΔΔCT threshold cycle (CT) method (48) and 18S rRNA as an internal control for
human cells and mouse tissues, and the results are plotted as relative values or fold change by
normalization to the values for mock-infected control samples. The primer sequences were as follows: for
inﬂuenza virus M1 protein, forward (Fw) primer 5=-AGATGAGTCTTCTAACCGAGTCG-3= and reverse (Rv)
primer 5=-TGCAAAAACATCTTCAAGTCTCT-3=; for 18S rRNA, Fw primer 5=-GTAACCCGTTGAACCCCATT-3=
and Rv primer 5=-CCATCCAATCGGTAGTAGCG-3=; for human IFN-, Fw primer 5=-TCTGGCACAACAGGTA
GTAGGC-3= and Rv primer 5=-GAGAAGCACAACAGGAGAGCAA-3=; for mouse IFN-, Fw primer 5=-CAGC
TCCAAGAAAGGACGAAC-3= and Rv primer 5=-GGCAGTGTAACTCTTCTGCAT-3=; for human IFIT1, Fw primer
5=-AGTGTGGGAATACACAACCTACT-3= and Rv primer 5=-GGTCACCAGACTCCTCACATTT-3=; for human
ISG15, Fw primer 5=-TCCTGGTGAGGAATAACAAGGG-3= and Rv primer 5=-GTCAGCCAGAACAGGTCGTC-3=;
and for human IFIT2, Fw primer 5=-GGAGGGAGAAAACTCCTTGGA-3= and Rv primer 5=-GGCCAGTAGGTT
GCACATTGT-3=.
Multiple-sequence alignment and protein model. The protein sequences of the PB2 proteins of
inﬂuenza viruses were obtained from the NIAID Inﬂuenza Research Database through the website at
http://www.ﬂudb.org. All sequences were grouped, resulting in a data set of 12,996 unique PB2 protein
sequences from different hosts, including viruses of swine, avian, human, and bat origin. The sequences
within the data sets were aligned using the MUSCLE (multiple-sequence comparison by log expectation)
algorithm. The sequences obtained from the alignments were compared using the Geneious tool (49),
calculating mean pairwise identities. Molecular graphics of the crystal structure of the HL17NL10
polymerase complex were prepared by superimposition (29) using the PyMOL molecular graphics system
(version 1.8; Schrödinger, LLC).
Minigenome polymerase activity assay. For reconstitution of the polymerase complex in HEK293T
cells, plasmids (A/Puerto Rico/8/1934) expressing the PB2 WT, the PB2 I503V and V249A mutants, PB1, PA
(each 50 ng), and NP (200 ng) were cotransfected with the ﬁreﬂy luciferase (FF-Luc)-expressing viral
minigenome construct pPoI-FFLuc-RT (200 ng) and a plasmid (pRL-TK; 50 ng) expressing the Renilla
luciferase. Expression of the minigenome was driven by the human polymerase promoter, as previously
described (5). Fireﬂy and Renilla luciferase activities were measured using a dual-luciferase reporter assay
at 24 h posttransfection (1910; Promega).
IFN- promoter assay. HEK293T cells in 24-well plates were cotransfected with plasmids (25 ng)
expressing PR8 NS1 as a control, the PB2 WT, and the PB2 V249A and I503V mutants, together with an
IFN- promoter-dependent ﬁreﬂy luciferase expression plasmid (50 ng) and a constitutively active Renilla
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luciferase expression plasmid (pRL-TK; 25 ng), which was used for normalization. The total amount of
plasmid DNA was kept constant with an empty expression vector. At 24 h posttransfection, the cells were
infected with a defective interfering (DI) particle-rich stock of Sendai virus (SeV) for 16 h to stimulate the
IFN- promoter. Fireﬂy and Renilla luciferase activities were measured using a dual-luciferase reporter
assay at 24 h posttransfection (1910; Promega).
Statistical analysis. Variables were expressed as the mean  standard deviation (SD) if the values
were adjusted to a normal distribution, and the results were evaluated by the Shapiro-Wilk or
Kolmogorov-Smirnov test when appropriate. For bivariate analysis of quantitative variables, the Mann-
Whitney test or Student’s t test was used on the basis of their distributions. If the variance was not
homogeneous (Levene test), the Welch test (analysis of variance [ANOVA]) was applied. Two-way ANOVA
with Bonferroni’s posttest was used for multiple comparisons. Statistical signiﬁcance was established at
a P value of 0.05. All reported P values are based on two-tailed tests.
Ethics statement. This study was carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals (50). All mouse procedures were approved by
Institutional Animal Care and Use Committee (IACUC) of the Icahn School of Medicine at Mount Sinai and
performed in accordance with the IACUC guidelines (protocol number IACUC-2013-1408, Center for
Research on Inﬂuenza Pathogenesis). All bat specimens were collected and processed after approval of
the Institutional Committee of Care and Use of Animals (IACUC) of the University of Costa Rica (permit
number CICUA-36-13) according to national guidelines for animal care described in the Costa Rica
National Law for Animal Welfare 7451.
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